Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 7 Issue 1

Low-dose Amiodarone in Prophylaxis of Atrial Fibrillation After Isolated On-pump Coronary Artery Bypass Surgery in Patients with Risk Factors for the Development of Postoperative Atrial Fibrillation

Elona Dado1, Edvin Dado2, Juna Musa3, Arghyadeep Ganguly3, Juliana Karanxha4,  Elizana Zaimi Petrela5, Edlira Horjeti6, Mrunal Teja Chinthapalli7,  Fjolla Hyseni8, Syeda Salima Sultana9, Blina Abdullahu10, Mohammad Abubaker SIDDIQUE11 and Efrosina Kajo12

1Cardiologist, Hygea Hospital Tirana

2Cardiologist, Faculty of Medicine, UMT, /"UHC " Mother Teresa" , Tirana

3Department of Endocrinology Diabetes and Nutrition Mayo Clinic Rochester Minnesota, USA

4Cardiologist, American Hospital 3, Tirana

5Professor of Medicine, UMT, Faculty of Medicine/ UHC "Mother TERESA", Tirana

6Research Fellow Department of Urology Mayo Clinic Rochester Minnesota, USA

7Department of Endocrinology Diabetes and Nutrition Mayo Clinic Rochester Minnesota, USA

8candidate NYU Langone Medical Center New York City, USA

9Southern Medical and College, Bangladesh

10Mother Teresa Hospital Tirane, Albania

11Northeast Medical College and Hospital Sylhet, Bangladesh

12Professor of Medicine, UMT, Faculty of Medicinem, Tirana

Minnesota, USA

*Corresponding Author: Juna Musa, Department of Endocrinology Diabetes and Nutrition Mayo Clinic Rochester Minnesota, USA.

Received: December 12, 2022; Published: December 27, 2022

Reprints View PDF Related Articles

×

Abstract

Objective: Atrial fibrillation (AFib) is the most common arrhythmia complicating cardiac surgery and remains common despite improvements in surgical techniques and perioperative management. Due to its high risk for significant morbidity and mortality, AFib prophylaxis is very important to improve outcomes. The purpose of this study was to investigate the efficacy of lower-dose oral Amiodarone therapy protocol for the prevention of Postoperative Atrial fibrillation (POAF) in patient undergoing on-pump isolated Coronary Artery By-pass Grafting (CABG) with risk factors for the development of postoperative atrial fibrillation (POAF).

Methods: To investigate the role of lower - dose Amiodarone therapy for the prevention of POAF in high-risk patients, we conducted a prospective, randomized, placebo-controlled, single blind study. 120 patients, aged 65 years and older and with EF≤40% who underwent elective and initial isolated CABG were enrolled in this study. Patient in the treatment group received oral Amiodarone, 2.4 g over 3 preoperative days, followed by 200 mg once daily regimen, for at least 6 days postoperatively.

Results: The incidence of POAF in the in the Amiodarone -treated group was significantly lower compared to the control group (18,3% vs 38,3% p = 0.015), with a Relative Risk of 0.48 times (95% CI: 0.26-0.89) and an estimated Number- Needed -to- Treat of 5 patients to prevent one additional case of POAF. The overall Intensive Care Unit (ICU) and hospital Length of stay (LOS) was significantly lower in the Amiodarone group compared to the control group (48 ± 9.1 vs 55 ± 15.4, p = 0.003 and 7.5 ± 0.99 vs 8.2 ± 1.4, p = 0.002, respectively). Patients who developed POAF in the Amiodarone group compared to the control group had a significant lower duration of Afib (18.2 ± 4.9 vs 36.6 ± 8.1, p = 0.001) and a significant lower ventricular rate (71.1 ± 2.7 vs 93.9 ± 8.6, p = 0.001).

Conclusion: Lower dose of oral Amiodarone therapy, resulted effective for the prevention of POAF in the patient population aged 65 years and older, with EF≤40%, who underwent on-pump isolated elective CABG. This beneficial effect in the reduction of POAF incidence and duration is associated with significant shorter ICU and hospital LOS in the Amiodarone treated group and is achieved without adverse effects.

Keywords: Atrial Fibrillation; Post-op; Prevention; Cardiac Surgery; Amiodarone

×

References

  1. Dobrev D., et al. “Postoperative atrial fibrillation: mechanisms, manifestations and management”. Nature Reviews Cardiology 16 (2019): 417-436.
  2. Funk M., et al. “Incidence, timing, symptoms, and risk factors for atrial fibrillation after cardiac surgery”. American Journal of Critical Care 5 (2003): 424-435.
  3. Kalman JM., et al. “Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation”. The Annals of Thoracic Surgery6 (1995): 1709-1715.
  4. Greenberg JW., et al. “Postoperative atrial fibrillation following cardiac surgery: a persistent complication”. European Journal of Cardio-Thoracic Surgery4 (2017): 665-672.
  5. Borzak S., et al. “Atrial fibrillation after bypass surgery: does the arrhythmia or the characteristics of the patients prolong hospital stay?” Chest 6 (1998): 1489-1491.
  6. Villareal RP., et al. “Postoperative atrial fibrillation and mortality after coronary artery bypass surgery”. Journal of the American College of Cardiology5 (2004): 742-748.
  7. Melby SJ., et al. “A time-related parametric risk factor analysis for postoperative atrial fibrillation after heart surgery”. The Journal of Thoracic and Cardiovascular Surgery3 (2015): 886-892.
  8. Hogue CW Jr and Hyder ML. “Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment”. The Annals of Thoracic Surgery1 (2000): 300-306.
  9. Mathew JP., et al. “Investigators of the Ischemia Research and Education Foundation, Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery”. JAMA14 (2004): 1720-1729.
  10. Amar D., et al. “Older age is the strongest predictor of postoperative atrial fibrillation”. Anesthesiology2 (2002): 352-356.
  11. Yamashita K., et al. “Clinical Risk Factors for Postoperative Atrial Fibrillation among Patients after Cardiac Surgery”. Thoracic and Cardiovascular Surgery2 (2019): 107-116.
  12. Alameddine AK., et al. “Blood transfusion and the risk of atrial fibrillation after cardiac surgery”. Journal of Cardiac Surgery 5 (2014): 593-599.
  13. Mitchell LB., et al. “Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial”. JAMA24 (2005): 3093-3100.
  14. Giri S., et al. “Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial”. Lancet9259 (2001): 830-836.
  15. Daoud EG., et al. “Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery”. The New England Journal of Medicine 25 (1997): 1785-1791.
  16. Budeus M., et al. “Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study”. European Heart Journal13 (2006): 1584-1591.
  17. White CM., et al. “Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II)”. Circulation 108 (2003): II200-II206.
  18. Guarnieri T., et al. “Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial”. Journal of the American College of Cardiology 2 (1999): 343-347.
  19. Beaulieu Y., et al. “Perioperative intravenous amiodarone does not reduce the burden of atrial fibrillation in patients undergoing cardiac valvular surgery”. Anesthesiology1 (2011): 128-137.
  20. Hindricks G., et al. “2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC)”. Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in European Heart Journal 42.5 (2021): 507.
  21. Frendl G., et al. “2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures”. The Journal of Thoracic and Cardiovascular Surgery 3 (2014): e153-e193.
  22. Kerwin M., et al. “New-onset atrial fibrillation and outcomes following isolated coronary artery bypass surgery: A systematic review and meta-analysis”. Clinic Cardiology9 (2020): 928-934.
  23. Ehrlich MP., et al. “Atrial Fibrillation After Cardiac Surgery: Electrophysiological Mechanism and Outcome”. The Annals of Thoracic Surgery6 (2020): 1765-1772.
  24. Wang H and Chow SC. “Sample Size Calculation for Comparing Proportions”. Wiley Encyclopedia of Clinical Trials.
  25. Dunning J., et al. “Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery”. European Journal of Cardio-Thoracic Surgery6 (2006): 852-872.
  26. Lewicki Ł., et al. “Atrial fibrillation following off-pump versus on-pump coronary artery bypass grafting: Incidence and risk factors”. Cardiology Journal5 (2016): 518-523.
  27. Almassi GH., et al. “Predictors and impact of postoperative atrial fibrillation on patients' outcomes: a report from the Randomized on Versus Off Bypass trial”. The Journal of Thoracic and Cardiovascular Surgery1 (2012): 93-102.
  28. Ali IM. “Interrupted warm blood cardioplegia”. European Journal of Cardio-Thoracic Surgery6 (1996): 480.
  29. Burgess DC., et al. “Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis”. European Heart Journal23 (2006): 2846-2857.
  30. Crystal E., et al. “Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis”. Circulation1 (2002): 75-80.
  31. Butler J., et al. “Amiodarone prophylaxis for tachycardias after coronary artery surgery: a randomised, double blind, placebo controlled trial”. British Heart Journal1 (1993): 56-60.
  32. Mitchell LB. “Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery”. Canadian Journal of Cardiology1 (2011): 91-97.
  33. Bagshaw SM., et al. “Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis”. The Annals of Thoracic Surgery5 (2006): 1927-1937.
  34. Buckley MS., et al. “Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation”. Pharmacotherapy3 (2007): 360-368.
  35. Arsenault KA., et al. “Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery”. Cochrane Database System Review1 (2013): CD003611.
  36. Auer J., et al. “A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial”. American Heart Journal4 (2004): 636-643.
  37. O'Brien B., et al. “Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists Practice Advisory for the Management of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery”. Journal of Cardiothoracic and Vascular Anesthesia 1 (2019): 12-26.
  38. Zhu J., et al. “Meta-analysis of amiodarone versus β-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery”. Internal Medical Journal 10 (2012): 1078-1087.
  39. Zimetbaum P. “Amiodarone for atrial fibrillation”. The New England Journal of Medicine9 (2007): 935-941.
  40. Papiris SA., et al. “Amiodarone: review of pulmonary effects and toxicity”. Drug Safety7 (2010): 539-558.
  41. Vassallo P and Trohman RG. “Prescribing amiodarone: an evidence-based review of clinical indications”. JAMA11 (2011): 1312-1322.
  42. Hamilton D Sr., et al. “Amiodarone: A Comprehensive Guide for Clinicians”. American Journal of Cardiovascular Drugs6 (2020): 549-558.
  43. Hauser TH., et al. “Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter”. American Journal of Cardiology9 (2004): 1173-1176.
  44. Trohman RG., et al. “Amiodarone and thyroid physiology, pathophysiology, diagnosis and management”. Trends Cardiovascular Medicine5 (2019): 285-295.
  45. Tokmakoglu H., et al. “Amiodarone versus digoxin and metoprolol combination for the prevention of postcoronary bypass atrial fibrillation”. European Journal of Cardio-Thoracic Surgery3 (2002): 401-405.
  46. Patti G., et al. “Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study”. Circulation14 (2006): 1455-1461.
  47. White CM., et al. “Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III”. European Journal of Cardio-Thoracic Surgery5 (2007): 817-820.
  48. Ahmed MA., et al. “Does prophylactic low-dose amiodarone decrease the incidence of postoperative atrial fibrillation after coronary artery bypass graft surgery? A randomized controlled trial”. Cardiothoracular Surgery24 (2022).
  49. Rho RW. “The management of atrial fibrillation after cardiac surgery”. Heart5 (2009): 422-429.
  50. Stanley TO., et al. “The impact of postoperative atrial fibrillation on neurocognitive outcome after coronary artery bypass graft surgery”. Anesthesia and Analgesia 2 (2002).
  51. Daoud EG., et al. “Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery”. The New England Journal of Medicine2.25 (1997): 1785-1791.
×

Citation

Citation: Juna Musa.,et al. “Low-dose Amiodarone in Prophylaxis of Atrial Fibrillation After Isolated On-pump Coronary Artery Bypass Surgery in Patients with Risk Factors for the Development of Postoperative Atrial Fibrillation". Acta Scientific Medical Sciences 7.1 (2023): 137-150.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US





Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta-Publications

ff

© 2021 Acta Scientific, All rights reserved.